Effects of serelaxin in patients admitted for acute heart failure: a meta‐analysis

Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU

(2019) Aldo P. Maggioni et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effects of Serelaxin in Patients with Acute Heart Failure

(2019) Marco Metra et al.   NEW ENGLAND JOURNAL OF MEDICINE

the Efficacy, Safety, and Tolerability of Additional Serelaxin Administration to Standard Therapy in Asian Patients with Acute Heart Failure: The RELAX-AHF-ASIA trial

(2018) Naoki Sato et al.   JOURNAL OF CARDIAC FAILURE

RELAX-AHF, BLAST-AHF, TRUE-AHF, and other important truths in acute heart failure research

(2017) Gad Cotter et al.   EUROPEAN JOURNAL OF HEART FAILURE

Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial

(2017) Naoki Sato et al.   JOURNAL OF CARDIAC FAILURE

Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF

(2016) Licette C. Y. Liu et al.   Clinical Research in Cardiology

RELAX-REPEAT: A Multicenter, Prospective, Randomized, Double-Blind Study Evaluating the Safety and Tolerability of Repeat Doses of Serelaxin in Patients with Chronic Heart Failure

(2016) John R. Teerlink et al.   JOURNAL OF CARDIAC FAILURE

Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study

(2015) Zhanna Kobalava et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure

(2015) Naoki Sato et al.   CIRCULATION JOURNAL

Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populat

(2015) Marion Dahlke et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Conducting Meta-Analyses inRwith themetaforPackage

(2015) Wolfgang Viechtbauer   Journal of Statistical Software

Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure

(2014) Adriaan A. Voors et al.   Circulation-Heart Failure

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure

(2013) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program

(2012) Marco Metra et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

(2012) John R Teerlink et al.   LANCET

Diuretic Strategies in Patients with Acute Decompensated Heart Failure

(2011) G. Michael Felker et al.   NEW ENGLAND JOURNAL OF MEDICINE

First Clinical Experience with Intravenous Recombinant Human Relaxin in Compensated Heart Failure

(2009) Thomas Dschietzig et al.   Annals of the New York Academy of Sciences

Intravenous Recombinant Human Relaxin in Compensated Heart Failure: A Safety, Tolerability, and Pharmacodynamic Trial

(2009) Thomas Dschietzig et al.   JOURNAL OF CARDIAC FAILURE

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study

(2009) John R Teerlink et al.   LANCET